* Coulter Pharmaceutical Inc., of Palo Alto, Calif., said it reached target enrollment in its pivotal Phase III clinical trial of Bexxar for non-Hodgkins lymphoma. The trial's target enrollment includes 61 patients with low-grade and transformed low-grade non-Hodgkin's lymphoma. Bexxar is an antibody conjugated to iodine 131. It attaches to a protein found only on the surface of B cells, including non-Hodgkin's B cells and some normal B cells, in order to provide a greater concentration of therapeutic radiation to tumor cells.

* Synaptic Pharmaceutical Corp., of Paramus, N.J., granted to Glaxo Wellcome plc, of London, a non-exclusive license to some of its alpha adrenergic receptor patents and an option for a nonexclusive license under Synaptic's functional use patents for the treatment of benign prostatic hyperplasia. Glaxo paid Synaptic $2 million up front. An additional payment will be made if the option, expiring May 22, 1999, is exercised.

No Comments